Business
Azenta supports life-sciences customers with sample management, automated storage, genomic services, consumables, informatics, and sample repository services.
Azenta grew revenue modestly, narrowed losses, expanded free cash flow, and kept forensic screens safe.
The read at a glance✓ Audited against SEC data
- Business mix — Sample management and multiomicsNote
- Revenue — Revenue rose 3.6%OK
- Losses — Net loss narrowed to $55.8MOK
- Cash — Free cash flow rose to $38.3MOK
- Balance sheet — Equity was roughly flatNote
- Insiders — 1 buy / 1 sellNote
- Accounting — Altman-Z, Beneish-M, and earnings-quality safeOK
Where the revenue comes from
Fiscal 2025, as Azenta, Inc. reports it. History and quarterly detail are in the app.
- Multiomics$269.2M
- Core Products$197.6M
- Sample Repository Solutions$127.0M
Leadership changes
From Azenta, Inc.'s own filings, the day they're filed.
- E. Martin III · President · appointmenteff. 2026-04-06
- Ginger Zhou · President · departureeff. 2026-04-06
- Alan P. Malus · Directors · departureeff. 2026-01-29
Latest filings
- 8-K · Company announcement2026-08-24
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-07-08
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Azenta, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.